ADAM N. GOLDFARB
Medical Practice at Lee St, Charlottesville, VA
License number
Virginia 0101057464
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
Lee St, Charlottesville, VA 22908
Phone
(434) 924-0000
Personal information
See more information about ADAM N. GOLDFARB at radaris.comName
Address
Phone
1824 Wayside Pl, Charlottesville, VA 22903
1824 Wayside Pl, Charlottesvle, VA 22903
Organization information
See more information about ADAM N. GOLDFARB at bizstanding.comAdam N Goldfarb MD
PO Box 800214, Charlottesville, VA 22908
Categories:
Pathology Physicians & Surgeons
Phone:
(434) 982-0593 (Phone)
Professional information
Dr. Adam N Goldfarb, Charlottesville VA - MD (Doctor of Medicine)
Address:
1215 Lee St, Charlottesville 22908
(434) 924-0000 (Phone), (434) 982-1850 (Fax)
Charlottesville Office
1215 Lee St, Charlottesville 22908
(434) 924-3627 (Phone), (434) 243-6618 (Fax)
(434) 924-0000 (Phone), (434) 982-1850 (Fax)
Charlottesville Office
1215 Lee St, Charlottesville 22908
(434) 924-3627 (Phone), (434) 243-6618 (Fax)
Hospitals:
1215 Lee St, Charlottesville 22908
Charlottesville Office
1215 Lee St, Charlottesville 22908
Charlottesville Office
1215 Lee St, Charlottesville 22908
Education:
Medical Schools
Tufts University
Graduated: 1986
Tufts University
Graduated: 1986
Adam N Goldfarb, Charlottesville VA
Specialties:
Pathologist
Address:
500 Ray C Hunt Dr, Charlottesville, VA 22903
Methods And Compounds Regulating The Erythroid Response To Iron Deficiency
US Patent:
2012014, Jun 7, 2012
Filed:
Oct 14, 2011
Appl. No.:
13/273345
Inventors:
Adam N. Goldfarb - Charlottesville VA, US
Loretta L. Delehanty - Charlottesville VA, US
Loretta L. Delehanty - Charlottesville VA, US
Assignee:
UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA
International Classification:
A61K 38/19, A61K 38/17, C07C 235/74, C07C 69/675, A61P 7/06, A61P 35/00, A61K 31/19, C12Q 1/25, H01J 49/26, A61P 7/00, G01R 33/44, A61K 31/225, A61K 31/22
US Classification:
514 77, 514547, 560155, 560176, 514546, 514557, 435 4, 250282, 324307
Abstract:
The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
Methods And Compounds Regulating The Erythroid Response To Iron Deficiency
US Patent:
2013007, Mar 21, 2013
Filed:
Nov 19, 2012
Appl. No.:
13/680325
Inventors:
Adam N. Goldfarb - Charlottesville VA, US
Loretta L. Delehanty - Charlottesville VA, US
Loretta L. Delehanty - Charlottesville VA, US
Assignee:
UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA
International Classification:
A61K 31/194, C12Q 1/25, C07C 69/704, A61K 31/19
US Classification:
514 54, 514574, 514557, 435 4, 560180, 73 6143, 73 2335, 324309
Abstract:
The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
Methods And Compounds Regulating The Erythroid Response To Iron Deficiency
US Patent:
2010018, Jul 22, 2010
Filed:
Aug 22, 2007
Appl. No.:
12/376593
Inventors:
Adam N. Goldfarb - Charlottesville VA, US
Loretta L. Delehanty - Charlottesville VA, US
Loretta L. Delehanty - Charlottesville VA, US
Assignee:
UNIVERSITY OF VIRGINIA PATENT FOUNDATION - Charlottesville VA
International Classification:
A61K 38/16, G01N 33/53, G01N 33/00, A61K 38/17, A61K 31/19, C07C 69/34
US Classification:
514 8, 435 71, 436129, 514 12, 514574, 560190
Abstract:
The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.